There is an overall trend toward more allogeneic-based products than autologous, particularly in trials scheduled for recent years.
← all excerpts
Stem Cell Therapies for Gastrointestinal and Liver Diseases: Translational Barriers, Clinical Heterogeneity, and Future Directions.
1
—
—